Related Experiment Video
Updated: Jan 27, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
RIPK1 inhibition attenuates experimental autoimmune arthritis via suppression of osteoclastogenesis
Jooyeon Jhun1, Seung Hoon Lee1,2, Se-Young Kim1
1The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, South Korea.
Background:
Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease characterized by upregulation of inflammatory cell death and osteoclastogenesis. Necrostatin (NST)-1s is a chemical inhibitor of receptor-interacting serine/threonine-protein kinase (RIPK)1, which plays a role in necroptosis.
Methods:
We investigated whether NST-1s decreases inflammatory cell death and inflammatory responses in a mouse model of collagen-induced arthritis (CIA).
Results:
NST-1s decreased the progression of CIA and the synovial expression of proinflammatory cytokines. Moreover, NST-1s treatment decreased the expression of necroptosis mediators such as RIPK1, RIPK3, and mixed lineage kinase domain-like (MLKL). In addition, NST-1s decreased osteoclastogenesis in vitro and in vivo. NST-1s downregulated T helper (Th)1 and Th17 cell expression, but promoted Th2 and regulatory T (Treg) cell expression in CIA mice.
Conclusions:
These results suggest that NST-1s attenuates CIA progression via the inhibition of osteoclastogenesis and might be a potential therapeutic agent for RA therapy.
Insights
Necrostatin (NST)-1s, a necroptosis inhibitor, reduced collagen-induced arthritis (CIA) progression by decreasing inflammation and osteoclastogenesis. This suggests NST-1s may be a potential therapeutic for rheumatoid arthritis (RA).
Area of Science:
- Immunology
- Rheumatology
- Cell Biology
Background:
- Rheumatoid arthritis (RA) is a systemic inflammatory disease marked by increased inflammatory cell death and osteoclastogenesis.
- Necrostatin (NST)-1s inhibits receptor-interacting serine/threonine-protein kinase (RIPK)1, a key mediator of necroptosis.
Purpose of the Study:
- To evaluate the efficacy of NST-1s in reducing inflammatory cell death and responses in a collagen-induced arthritis (CIA) mouse model.
- To determine if NST-1s impacts osteoclastogenesis and T helper cell differentiation in CIA.
Main Methods:
- Administration of NST-1s to mice with collagen-induced arthritis (CIA).
- Assessment of disease progression, synovial expression of proinflammatory cytokines, and necroptosis mediators (RIPK1, RIPK3, MLKL).
- In vitro and in vivo evaluation of osteoclastogenesis and T helper cell populations (Th1, Th17, Th2, Treg).
Main Results:
- NST-1s treatment significantly decreased CIA progression and synovial expression of proinflammatory cytokines.
- NST-1s reduced the expression of necroptosis mediators, including RIPK1, RIPK3, and MLKL.
- The treatment inhibited osteoclastogenesis and modulated T helper cell profiles, favoring Th2 and Treg cells while downregulating Th1 and Th17 cells.
Conclusions:
- NST-1s effectively attenuates collagen-induced arthritis (CIA) progression.
- Inhibition of osteoclastogenesis and modulation of immune cell responses are key mechanisms of NST-1s action.
- NST-1s shows potential as a therapeutic agent for rheumatoid arthritis (RA).
More Related Videos
Related Concept Videos
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
Feedback Inhibition
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Enzyme Inhibition
Inhibition of Cdk Activity
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...

